Cilengitide in Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck (SCCHN)

NCT00705016 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

184

Enrollment

INDUSTRY

Sponsor class

Conditions

Squamous Cell Cancer

Interventions

DRUG: Cilengitide 2000 mg once weekly
DRUG: Cilengitide 2000 mg twice weekly
DRUG: Cetuximab
DRUG: 5-fluorouracil (5-FU)
DRUG: Cisplatin

Sponsor

Merck KGaA, Darmstadt, Germany